{"filing":{"accession_number":"0001829126-26-006773","cik":"0001979414","ticker":"NTHI","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"neonctechnologies_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626006773/neonctechnologies_8k.htm"},"events":[{"id":13257,"run_id":11765,"accession_number":"0001829126-26-006773","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces that the Department of Health – Abu Dhabi has granted Investigational New Drug (IND) status for NEO100, the Company's lead candidate. This is a material regulatory milestone that expands the Company's clinical development footprint internationally and enables advancement of multiple stages of clinical development in parallel across three protocols. While this is a significant operational and regulatory achievement for a clinical-stage biopharmaceutical company, it does not fit neatly into the specific event categories (it is not an earnings release, M\u0026A activity, impairment, litigation, or other named types), making it an operational_other event that would materially affect a reasonable investor's assessment of the registrant's development progress.","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10350,"accession_number":"0001829126-26-006773","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces that the Department of Health – Abu Dhabi has granted Investigational New Drug (IND) status for NEO100, the Company's lead candidate. This is a material regulatory milestone that expands the Company's clinical development footprint internationally and enables advancement of multiple stages of clinical development in parallel across three protocols. While this is a significant operational and regulatory achievement for a clinical-stage biopharmaceutical company, it does not fit neatly into the specific event categories (it is not an earnings release, M\u0026A activity, impairment, litigation, or other named types), making it an operational_other event that would materially affect a reasonable investor's assessment of the registrant's development progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T21:01:58.837641+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10350,"accession_number":"0001829126-26-006773","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces that the Department of Health – Abu Dhabi has granted Investigational New Drug (IND) status for NEO100, the Company's lead candidate. This is a material regulatory milestone that expands the Company's clinical development footprint internationally and enables advancement of multiple stages of clinical development in parallel across three protocols. While this is a significant operational and regulatory achievement for a clinical-stage biopharmaceutical company, it does not fit neatly into the specific event categories (it is not an earnings release, M\u0026A activity, impairment, litigation, or other named types), making it an operational_other event that would materially affect a reasonable investor's assessment of the registrant's development progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T21:01:58.837641+00:00","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","filing_date":"2026-06-23"}]}